Drug Type Herbal medicine |
Synonyms Withania somnifera roots extract |
Target |
Mechanism SLC8A3 agonists(solute carrier family 8 member A3 agonists) |
Active Indication |
Inactive Indication |
Originator Organization- |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Phase 2 | CA | 19 Oct 2021 | |
Schizophrenia | Phase 1 | US | 01 Dec 2018 | |
Alzheimer Disease | Preclinical | CN | 20 Dec 2022 | |
Alzheimer Disease | Preclinical | US | 20 Dec 2022 | |
Generalized anxiety disorder | Discovery | IN | 01 Mar 2011 |
Phase 2/3 | 47 | (Withania Somnifera Extract (WSE)) | kghjhhydou(ttndcsurya) = cbqjvqbdhg lodpznzfhp (pfpiwdvrzt, usdvaohesk - twbnlzpbre) View more | - | 08 Oct 2024 | ||
Placebo Oral Tablet (Placebo Tablets) | kghjhhydou(ttndcsurya) = cgwfxdgppd lodpznzfhp (pfpiwdvrzt, fvoywdrxan - upvdkirarz) View more |